Related references
Note: Only part of the references are listed.Targeting Triple-Negative Breast Cancer: The Lessons Learned From BRCA1-Associated Breast Cancers
Rita Nanda
SEMINARS IN ONCOLOGY (2011)
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
Daniel P. Silver et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Triple-negative breast cancer: disease entity or title of convenience?
Lisa Carey et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer
G. Frasci et al.
ANNALS OF ONCOLOGY (2009)
Triple-negative breast cancer-current status and future directions
O. Gluz et al.
ANNALS OF ONCOLOGY (2009)
Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
T. Byrski et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
A Phase II Trial of a Neoadjuvant Platinum Regimen for Locally Advanced Breast Cancer: Pathologic Response, Long-Term Follow-up, and Correlation With Biomarkers
Rinat Yerushalmi et al.
CLINICAL BREAST CANCER (2009)
Triple Receptor-Negative Breast Cancer: The Effect of Race on Response to Primary Systemic Treatment and Survival Outcomes
Shaheenah Dawood et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Platinum-based chemotherapy in triple-negative breast cancer
B. Sirohi et al.
ANNALS OF ONCOLOGY (2008)
Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors
Norazizah Shafee et al.
CANCER RESEARCH (2008)
Triple-Negative Breast Cancer: Risk Factors to Potential Targets
Bryan P. Schneider et al.
CLINICAL CANCER RESEARCH (2008)
Basal-like subtype and BRCA1 dysfunction in breast cancers
Yasuo Miyoshi et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2008)
Basal-like breast cancer: A critical review
Emad A. Rakha et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
Cornelia Liedtke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Triple-negative breast cancer: Clinical features and patterns of recurrence
Rebecca Dent et al.
CLINICAL CANCER RESEARCH (2007)
HER-2/neu status and response to CMF:: retrospective study in a series of operable breast cancer treated with primary CMF chemotherapy
Catalina Falo et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2007)
Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data meta-analysis
Andrea Ardizzoni et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes
Lisa A. Carey et al.
CLINICAL CANCER RESEARCH (2007)
Basal-like breast carcinomas: clinical outcome and response to chemotherapy
S. Banerjee et al.
JOURNAL OF CLINICAL PATHOLOGY (2006)
Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast
L. G. Fulford et al.
HISTOPATHOLOGY (2006)
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
Lisa A. Carey et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma
CA Livasy et al.
MODERN PATHOLOGY (2006)
BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis
William D. Foulkes
FAMILIAL CANCER (2006)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma
TO Nielsen et al.
CLINICAL CANCER RESEARCH (2004)
The role of BRCA1 in the cellular response to chemotherapy
RD Kennedy et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Expression of luminal and basal cytokeratins in human breast carcinoma
DMA El-Rehim et al.
JOURNAL OF PATHOLOGY (2004)
Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome
M van de Rijn et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial
R Rosell et al.
ANNALS OF ONCOLOGY (2002)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin
A Bhattacharyya et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
